How Are Developers Moving Beyond CD19 in Autoimmune Cell Therapy?

Few targets have shaped the autoimmune cell therapy landscape more than CD19. The success of CD19-directed therapies helped establish the idea that deep B-cell depletion could produce meaningful clinical responses in autoimmune disease. For many companies, it provided some of the strongest evidence yet that immune reset may be achievable beyond oncology. As a result, much of the field's early momentum has been built around CD19-targeted approaches.

Today, however, the conversation is starting to broaden. As clinical data matures and more programs enter development, companies are increasingly asking whether CD19 alone can address the complexity of autoimmune disease. Different indications are driven by different immune mechanisms, and achieving durable responses may require more than a single targeting strategy.

Key Takeaways:

CD19 remains one of the most clinically validated targets in autoimmune cell therapy

Interest in new targets is being driven by disease heterogeneity, safety considerations, and the search for more precise immune modulation

Developers are exploring alternative B-cell approaches, T-cell targets, regulatory pathways, and multi-target strategies

Target selection is becoming a key factor in durability, patient selection, and long-term commercial success

The future of autoimmune cell therapy is likely to involve multiple targeting approaches rather than a single dominant target

Why Has CD19 Been So Important?

What Is CD19?

CD19 is a protein found on many B-cells and has become a widely used target in cell therapy because it enables deep and sustained B-cell depletion.

This approach has particular relevance in autoimmune disease, where B-cells can contribute to autoantibody production, antigen presentation, and broader immune dysfunction. By eliminating these populations, developers aim to interrupt the disease process and create the conditions for immune reconstitution.

The clinical progress seen with several CD19-focused programs has helped validate this strategy and given the industry confidence that cell therapy may have a meaningful role in autoimmune disease treatment.

Why Are Companies Looking Beyond CD19?

The move beyond CD19 is not about abandoning a successful target. Instead, it reflects a growing appreciation of how diverse autoimmune diseases really are.

Conditions such as lupus, rheumatoid arthritis, systemic sclerosis, myositis, and type 1 diabetes involve different cellular drivers, immune pathways, and patterns of disease progression. While B-cell depletion may be effective in many settings, it may not be the optimal solution for every patient or indication.

This has led developers to ask several important questions:

Are there disease-specific targets that could improve outcomes?
Can efficacy be maintained while reducing treatment burden?
Is broad immune-cell depletion always necessary?
Could more selective approaches improve safety and long-term tolerability?

These questions are helping shape the next generation of autoimmune cell therapy programs.

The Shift Toward Precision Immune Modulation

One of the clearest trends emerging across the field is a move toward greater precision. Early autoimmune cell therapy programs were largely focused on eliminating pathogenic immune cells. Increasingly, developers are also evaluating how immune responses can be modulated, redirected, or regulated rather than broadly depleted.

The goal is not simply to remove harmful cells but to create a more durable and balanced immune state while minimizing unnecessary disruption to the wider immune system. This shift reflects a broader understanding that autoimmune diseases are biologically complex and may require more tailored therapeutic strategies.

Which Targets Are Attracting Attention?

While individual pipelines differ considerably, several themes are emerging across the autoimmune cell therapy landscape.

Alternative B-Cell Targets

T-Cell Directed Approaches

Multi-Target and Combination Approaches

Many developers continue to view B-cells as central drivers of disease but are investigating whether specific B-cell populations can be targeted more precisely.

Rather than replacing CD19 entirely, these efforts aim to better understand which cell populations are most relevant in different disease settings.

The growing interest in Treg therapies highlights the industry's focus on immune regulation.

Companies including GentiBio, Quell Therapeutics, PolTREG, and TR1X Therapeutics are pursuing approaches designed to restore immune tolerance rather than relying solely on cell depletion.

Some companies are exploring whether a single target will be sufficient for highly heterogeneous diseases.

Multi-target constructs and combination strategies are attracting attention as developers seek deeper responses, greater durability, and improved disease control across diverse patient populations.

What Developers Are Evaluating

As target selection becomes more sophisticated, several strategic questions are coming into focus:

Which immune-cell populations are most strongly linked to disease activity?

How much immune depletion is required to achieve durable remission?

Can immune tolerance be restored without broad suppression of the immune system?

Which biomarkers can guide target selection?

Will different autoimmune diseases ultimately require different targeting strategies?

These questions increasingly sit at the center of discovery, translational, and clinical development efforts.

Why Target Selection Matters Beyond Biology

Target selection is often viewed as a scientific decision, but it can also influence the broader development strategy.

The target a company pursues may affect patient selection, clinical trial design, safety monitoring, regulatory strategy, and commercial positioning. As autoimmune cell therapies move toward larger patient populations, developers must consider not only whether a target is biologically relevant, but whether it supports a practical and scalable treatment approach.

Where Target Selection Goes Next

As developers continue to build on the success of CD19, the focus is shifting toward a broader question: which targets are best positioned to deliver durable, safe, and scalable immune reset across different autoimmune diseases?

Rather than replacing CD19, the next generation of programs is expanding the industry's understanding of how immune reset can be achieved and which patients may benefit most from different therapeutic approaches. The result is a more diverse and increasingly sophisticated development landscape, where target selection is becoming one of the most important strategic decisions facing autoimmune cell therapy developers.